PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-3.64%
Negative revenue growth while MRVL stands at 2.80%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-4.17%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-13.26%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-12.91%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-20.48%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-19.48%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-19.74%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
-0.21%
Share reduction while MRVL is at 1.50%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.19%
Reduced diluted shares while MRVL is at 2.02%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
0.21%
Maintaining or increasing dividends while MRVL cut them. John Neff might see a strong edge in shareholder returns.
-52.12%
Negative OCF growth while MRVL is at 133.99%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-57.63%
Negative FCF growth while MRVL is at 152.49%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
72.62%
10Y revenue/share CAGR under 50% of MRVL's 272.09%. Michael Burry would suspect a lasting competitive disadvantage.
16.03%
5Y revenue/share CAGR under 50% of MRVL's 124.99%. Michael Burry would suspect a significant competitive gap or product weakness.
10.46%
3Y revenue/share CAGR under 50% of MRVL's 51.00%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
89.65%
10Y OCF/share CAGR under 50% of MRVL's 779.30%. Michael Burry would worry about a persistent underperformance in cash creation.
1.26%
Below 50% of MRVL's 99.27%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
48.44%
3Y OCF/share CAGR at 50-75% of MRVL's 67.91%. Martin Whitman would suspect weaker recent execution or product competitiveness.
159.95%
Below 50% of MRVL's 618.61%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
17.70%
Below 50% of MRVL's 209.32%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
170.91%
Positive short-term CAGR while MRVL is negative. John Neff would see a clear advantage in near-term profit trajectory.
41.87%
Below 50% of MRVL's 123.97%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
24.85%
Below 50% of MRVL's 55.97%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
2.50%
Below 50% of MRVL's 23.04%. Michael Burry suspects a serious short-term disadvantage in building book value.
1248.38%
Dividend/share CAGR of 1248.38% while MRVL is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
182.07%
Dividend/share CAGR of 182.07% while MRVL is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
99.80%
3Y dividend/share CAGR of 99.80% while MRVL is zero. Bruce Berkowitz sees a minor positive difference that could attract dividend-focused investors.
11.88%
AR growth well above MRVL's 14.02%. Michael Burry fears inflated revenue or higher default risk in the near future.
3.36%
Inventory growth well above MRVL's 0.80%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
-2.12%
Negative asset growth while MRVL invests at 4.26%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
0.01%
Under 50% of MRVL's 0.29%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.
-0.09%
We’re deleveraging while MRVL stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
8.68%
R&D growth drastically higher vs. MRVL's 2.24%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
2.33%
SG&A declining or stable vs. MRVL's 9.36%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.